Ligandrol LGD-4033: What the Clinical Evidence Actually Shows

What Is Ligandrol LGD-4033?

LGD-4033 is a non-steroidal small molecule that binds the androgen receptor with high affinity and selectivity. Viking Therapeutics licensed the compound from Ligand Pharmaceuticals and has advanced it under the designation VK5211 for hip-fracture muscle recovery. Unlike testosterone, LGD-4033 was designed to activate androgen receptors preferentially in muscle and bone while producing less stimulation in prostate and sebaceous tissue, though that tissue selectivity has not been confirmed to be absolute in humans.

The compound was first described in peer-reviewed literature by Basaria et al. in a 2013 randomized, double-blind, placebo-controlled Phase I trial published in the Journals of Gerontology [1]. Healthy men aged 21 to 50 received 0.1 mg, 0.3 mg, 1 mg, or placebo once daily for 21 days. All active doses produced statistically significant lean mass increases. The 1 mg group gained a mean of 1.21 kg of lean body mass above placebo (P<0.001), with no change in fat mass and no serious adverse events during the treatment window [1].

Viking Therapeutics reported Phase II results for VK5211 (LGD-4033) in hip-fracture patients in 2017. At 0.5 mg and 2 mg daily over 12 weeks, the compound produced dose-dependent lean mass accrual and functional improvements versus placebo, though the full dataset was disclosed only in a company press release and has not been published in a peer-reviewed journal as of the date of this review [2].

How LGD-4033 Affects Testosterone and the HPG Axis

Testosterone suppression is the most consistently documented adverse effect of LGD-4033 in human data. In the Basaria 2013 trial, total testosterone fell in a dose-dependent manner across all active arms, with the 1 mg group showing the steepest decline [1]. The suppression appeared reversible: testosterone levels trended back toward baseline within the 5-week follow-up period, though the authors noted that 21 days may be too short a window to characterize full recovery [1].

The mechanism is straightforward. Exogenous androgen-receptor agonism signals the hypothalamus to reduce gonadotropin-releasing hormone (GnRH) pulse frequency. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) fall as a result, and testicular testosterone synthesis drops [3]. This is the same axis suppressed by anabolic-androgenic steroids, which is why the recreational bodybuilding claim that SARMs are "side-effect free" is not supported by the pharmacology or the clinical data.

Sex hormone-binding globulin (SHBG) also fell significantly in the Basaria trial across all active doses [1]. Lower SHBG transiently raises free testosterone early in administration, which may partly explain anecdotal reports of rapid early strength gains. That effect is self-limiting as total testosterone suppression deepens over longer exposures.

The FDA's 2017 and 2023 safety communications on SARMs as a class specifically cite HPG-axis suppression, liver toxicity, and stroke risk as documented harms [4]. The agency has issued warning letters to multiple supplement companies marketing LGD-4033-containing products as dietary supplements, noting that SARMs do not meet the statutory definition of a dietary supplement under 21 U.S.C. 321(ff) [4].

Liver Safety: Case Reports and Mechanism

Hepatotoxicity is the second major safety signal in the published literature. At least four peer-reviewed case reports document cholestatic liver injury temporally associated with LGD-4033 use, with patients presenting with jaundice, pruritus, and elevated alkaline phosphatase [5][6]. In one 2020 case series published in BMJ Open Gastroenterology, two young men developed biopsy-confirmed cholestatic hepatitis after using LGD-4033 purchased online [5]. Liver enzyme normalization required 3 to 4 months after discontinuation in both cases.

The proposed mechanism involves androgen-receptor-mediated inhibition of bile-salt export pump (BSEP) expression in hepatocytes, a pathway shared with some anabolic steroids [6]. Because LGD-4033 is not 17-alpha-alkylated, early claims held that it would be liver-safe. The case-report literature does not support that assumption.

Baseline liver function testing before any SARM use, and repeat testing every 4 to 6 weeks during use, is the minimum monitoring standard endorsed by harm-reduction frameworks referenced in addiction-medicine literature [7]. Any elevation of alanine aminotransferase (ALT) above three times the upper limit of normal warrants immediate discontinuation.

LGD-4033 Dosing in Clinical Trials vs. Recreational Practice

The highest dose used in a controlled human trial is 22 mg per day, studied in the Basaria 2013 Phase I dose-escalation cohort [1]. Meaningful lean mass accrual occurred at just 1 mg per day, a dose far below the 5 to 10 mg per day commonly reported on bodybuilding forums. There is no published human safety or efficacy data for doses above 22 mg, and there is no published data for cycles exceeding 12 weeks.

Recreational users frequently self-administer 5 to 10 mg daily for 8 to 12 weeks, sometimes stacked with other investigational compounds. The FDA and the U.S. Anti-Doping Agency (USADA) have both issued public warnings that products sold online as "research chemicals" often contain incorrect doses or unlisted ingredients [4][8]. Independent laboratory testing by organizations such as the Banned Substances Control Group has found label inaccuracy rates exceeding 50% in sampled SARM products [8].

Post-cycle therapy (PCT) with a selective estrogen receptor modulator such as clomiphene or tamoxifen is widely practiced in the recreational community after LGD-4033 cycles. No randomized controlled trial has evaluated PCT efficacy after SARM use specifically, and the practice is entirely off-label [9].

Comparing LGD-4033 to Other SARMs: Ostarine, RAD-140, Cardarine, and Stenabolic

These five compounds are frequently discussed together in body-composition contexts, but their pharmacology, evidence bases, and risk profiles differ significantly.

Ostarine (MK-2866, enobosarm) has the most extensive clinical dataset of any SARM. Two Phase III trials (POWER 1 and POWER 2, Enobosarm-1 and Enobosarm-2) enrolled cancer patients with muscle-wasting and found that 3 mg daily over 147 days produced statistically significant lean mass gains, though the trials failed their primary regulatory endpoints for stair-climb power [10]. Ostarine is the most studied SARM in humans and has a longer published safety record than LGD-4033. Its anabolic potency per milligram is lower; typical Phase II doses were 1 to 3 mg versus LGD-4033's 1 mg producing comparable lean mass accrual at 21 days [1][10].

RAD-140 (testolone) has completed only preclinical studies in primates and cell lines as of 2025. A 2020 case report in ACG Case Reports Journal documented acute liver failure requiring hospitalization in a 49-year-old man who self-administered RAD-140 purchased online [11]. No Phase I human pharmacokinetic or safety data has been published in a peer-reviewed journal. RAD-140 is the least characterized of the commonly discussed SARMs from a human-evidence standpoint.

Cardarine (GW-501516) is not a SARM at all. It is a peroxisome proliferator-activated receptor delta (PPARδ) agonist. GSK halted its development in 2007 after preclinical studies showed rapid carcinogenesis in multiple tissue types at doses extrapolated to human use [12]. The FDA issued a specific safety alert for GW-501516 in 2013, stating that "GW501516 caused cancer in animal studies at all doses" [12]. No human efficacy or safety trials have been completed. Cardarine has no legitimate place in a medically supervised protocol.

Stenabolic (SR-9009) is a Rev-ErbA agonist, not an androgen receptor modulator. It has demonstrated metabolic and endurance effects in rodent models, including a 2013 study in Nature Medicine showing 50% increased running distance in mice [13]. Critically, SR-9009 has extremely poor oral bioavailability in mammals, a finding confirmed in pharmacokinetic modeling. No published human pharmacokinetic study exists. Whether oral SR-9009 produces meaningful plasma concentrations in humans is genuinely unknown [13].

LGD-4033 has the best human efficacy-to-dose ratio of the four compounds discussed here, based on the available Phase I lean-mass data. It also has the most characterized suppression profile. That is not an endorsement; it means the known risks are better described.

WADA Prohibition and Athletic Testing

WADA added SARMs as a class to the Prohibited List in 2008 under Section S1.2 (Other Anabolic Agents) [14]. LGD-4033 is prohibited both in-competition and out-of-competition, meaning a positive test during the off-season carries the same sanction as one taken on race day.

Urine detection methods have advanced substantially. A 2015 study in Drug Testing and Analysis identified LGD-4033 metabolites in doping-control urine samples up to 22 days after a single 10 mg oral dose [15]. Current accredited WADA laboratories use liquid chromatography-high-resolution mass spectrometry (LC-HRMS) that can detect nanogram-per-milliliter concentrations. Several high-profile doping cases involving LGD-4033 have resulted in multi-year bans across rugby, athletics, and mixed martial arts [14].

The detection window of up to 22 days means that even a single recreational dose within three weeks of an in-competition test carries meaningful detection risk [15].

Cardiovascular and Lipid Signals

Cardiovascular data from LGD-4033 trials is limited, but available signals warrant attention. The Basaria 2013 trial reported a dose-dependent decrease in HDL cholesterol, with the 1 mg group showing a mean HDL reduction of approximately 8 mg/dL at 21 days [1]. HDL suppression is a recognized class effect of androgens and anabolic steroids [16]. Whether LGD-4033's HDL reduction translates to increased atherosclerotic risk over longer exposure periods has not been studied in a controlled trial.

The American Heart Association's 2019 scientific statement on the cardiovascular effects of androgenic-anabolic steroids notes that even short-term androgen exposure can produce measurable adverse lipid changes and left-ventricular remodeling in susceptible individuals [16]. LGD-4033 has not been studied in cardiac imaging endpoints. Its long-term cardiovascular safety profile is genuinely unknown.

Blood pressure changes were not statistically significant in the Basaria 2013 trial at the doses and duration studied [1]. Hematocrit, a concern with testosterone therapy due to erythrocytosis, did not change significantly at 21 days, though longer exposure data is not available in peer-reviewed form.

Regulatory and Legal Status in the United States

LGD-4033 does not hold FDA approval for any indication [4]. It is not a scheduled controlled substance under the Controlled Substances Act as of the date of this article, which places it in a regulatory grey zone. Selling it as a dietary supplement violates the Federal Food, Drug, and Cosmetic Act [4]. Selling it labeled as a "research chemical for in-vitro use only" exists in contested legal territory; the FDA has pursued enforcement against multiple vendors under its adulterated-supplement authority [4].

Possession for personal use has not resulted in federal prosecution in documented cases, but that reflects enforcement priority rather than legal permissibility. State law varies. Several states have enacted their own SARM-specific legislation. Anyone considering LGD-4033 should consult legal counsel regarding their jurisdiction before purchase or use.

Clinical Contexts Where LGD-4033 May Eventually Have a Role

The legitimate investigational rationale for LGD-4033 is muscle-wasting associated with hip fracture, cancer cachexia, or age-related sarcopenia. The Viking Therapeutics Phase II hip-fracture data suggested functional benefit at low doses [2]. A 2022 review in Current Opinion in Clinical Nutrition and Metabolic Care identified SARMs as a class among the most promising pharmacological candidates for sarcopenia pending further Phase III data [17]. The American Society for Bone and Mineral Research has also noted that tissue-selective anabolic agents represent an unmet need in fracture recovery [17].

None of this translates to a currently approvable indication. LGD-4033 has not completed Phase III trials. Phase III failure rates for investigational compounds exceed 50% [18]. Until Phase III data exists, the compound remains experimental by any standard definition.

What HealthRX Prescribes Instead for Legal Muscle-Preservation Goals

HealthRX physicians do not prescribe LGD-4033 or any unapproved SARM. For patients with documented hypogonadism and body-composition goals, testosterone replacement therapy (TRT) has decades of Phase III and post-marketing safety data, established dosing protocols, and FDA approval [19]. For patients without hypogonadism seeking lean-mass preservation during caloric restriction, evidence-based options include adequate dietary protein (1.6 to 2.2 g per kg body weight per day, per the International Society of Sports Nutrition position stand [20]), resistance training, and creatine monohydrate (3 to 5 g per day), which has a Cochrane-reviewed efficacy record for lean mass in older adults [21].

Patients presenting with questions about SARMs should receive a full metabolic panel, total and free testosterone, LH, FSH, complete blood count, and liver function panel before any discussion of risk stratification. If LGD-4033 has already been used, repeat liver function testing 6 weeks after last dose is the minimum appropriate follow-up [7].